{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022610","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-05-13T11:30:50+00:00","discovered_at":"2026-05-13T11:35:00.272589+00:00","generated_at":"2026-05-13T11:38:35.171423+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Abeona Q1 net product revenue $8.7M; three ZEVASKYN patients treated; in-licenses PSMA T-cell therapy","bullets":["Net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025; net loss $17.1M ($0.30/sh).","Cash and investments $168.3M as of March 31, 2026, down from $191.4M at year-end 2025.","Three patients treated with ZEVASKYN in Q1 2026; QTC network expanded to six sites including CHOP and Columbia.","In-licensed ABO-701 (PSMA-SIR-T) engineered T-cell therapy for prostate cancer; IND expected H2 2027.","Deprioritized in-house ophthalmology programs to focus on ZEVASKYN and ABO-701."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022610","json":"https://secwatch.observer/filing/0001493152-26-022610.json","markdown":"https://secwatch.observer/filing/0001493152-26-022610.md","text":"https://secwatch.observer/filing/0001493152-26-022610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/0001493152-26-022610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T11:38:35.171423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eddddd417a3f263e97fbe7bda7fa1a313fa9616f","claim":"ABEONA THERAPEUTICS INC. reported first quarter ended March 31, 2026 results: revenue $8.7 million, net income $(17.1) million, EPS $(0.30) per basic and diluted common share.","evidence_excerpt":"Abeona reported net product revenue of $8.7 million in the first quarter ending March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/0001493152-26-022610-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$8.7 million"},{"label":"Net income","value":"$(17.1) million"},{"label":"EPS","value":"$(0.30) per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}